ATM mutation in aggressive uterine adenosarcoma in which systemic chemotherapies had remarkable effects

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• Molecular Pathology

Background:

• Uterine adenosarcoma is a rare gynecologic malignancy with a subset exhibiting aggressive clinical behavior.
• While TP53 mutations are common in high-grade tumors, definitive genetic alterations remain largely unidentified.
• Homologous recombination deficiency (HRD)-related gene mutations have not been previously reported in uterine adenosarcomas.

Observation:

• This study details a case of uterine adenosarcoma without sarcomatous overgrowth but with aggressive clinical behavior.
• The tumor harbored a TP53 mutation.
• The patient also presented with an ATM mutation, a gene implicated in homologous recombination deficiency.

Findings:

• The presence of both TP53 and ATM mutations in this aggressive uterine adenosarcoma case.
• The patient demonstrated a favorable response to platinum-based chemotherapy.
• The ATM mutation suggests potential susceptibility to poly(ADP-ribose) polymerase (PARP) inhibitors.

Implications:

• Identifies novel genetic alterations (TP53 and ATM mutations) in an aggressive uterine adenosarcoma.
• Highlights the potential of platinum-based chemotherapy and PARP inhibitors as therapeutic strategies for uterine adenosarcoma with HRD.
• Suggests further investigation into the role of HRD genes in uterine adenosarcoma pathogenesis and treatment response.